Pulmonary function testing after stereotactic body radiotherapy to the lung.

Area of Science:

• Pulmonology
• Oncology
• Radiotherapy

Background:

• Surgical resection is standard for early-stage non-small-cell lung cancer (NSCLC).
• Some patients are inoperable due to comorbidities like chronic obstructive pulmonary disease (COPD).
• Stereotactic body radiotherapy (SBRT) is an alternative treatment for lung cancer.

Purpose of the Study:

• To evaluate pulmonary function and tumor volume changes after SBRT.
• To compare outcomes in early-stage lung cancer patients with and without COPD.

Main Methods:

• Retrospective review of Stage I and II NSCLC patients treated with SBRT (60 Gy in 3 fractions).
• Patients categorized based on COPD status using American Thoracic Society guidelines.
• Pulmonary function tests (FEV%, DLCO) and tumor volume assessed pre- and post-treatment.

Main Results:

• SBRT did not significantly alter FEV% or FVC in either COPD or No-COPD groups.
• DLCO significantly improved in the No-COPD group but remained unchanged in the COPD group.
• Tumor volume significantly decreased in the No-COPD group and showed a trend toward shrinkage in the COPD group.

Conclusions:

• SBRT effectively shrinks tumors and improves DLCO in early-stage lung cancer patients without COPD.
• SBRT did not demonstrate significant effects on pulmonary function or tumor volume in patients with COPD.